Skip to main content
Top
Published in: Diabetes Therapy 5/2018

Open Access 01-10-2018 | Original Research

Diabetes Management and Healthcare Resource Use When Intensifying from Basal Insulin to Basal-Bolus: A Survey of Type 2 Diabetes Patients

Authors: Kathryn M. Pfeiffer, Amaury Basse, Xin Ying Lee, Laura Tesler Waldman

Published in: Diabetes Therapy | Issue 5/2018

Login to get access

Abstract

Introduction

Currently, there is limited knowledge about the experiences and challenges type 2 diabetes (T2D) patients face when intensifying from basal insulin to more complex regimens. The purpose of this study was to examine the experiences of adults with T2D who have been intensified to a basal-bolus insulin regimen, including challenges related to intensification, medication adherence issues, non-persistence, and healthcare resource use related to intensification.

Methods

A web-based survey of adults diagnosed with T2D and currently treated with basal insulin was conducted in the UK and the USA. The analysis sample was restricted to respondents with current/recent basal-bolus treatment (n = 398) and divided into three analysis groups: (1) “basal-bolus adherent” (current basal-bolus treatment with at least 90% adherence); (2) “basal-bolus non-adherent” (current basal-bolus treatment with less than 80% adherence); and (3) “stopped bolus” (discontinued bolus in past 12 months).

Results

Basal-bolus non-adherent respondents reported fewer discussions with their healthcare providers (HCPs) before starting bolus and more frequent difficulties with and worries about taking bolus insulin compared to basal-bolus adherent and stopped bolus groups. The most frequently reported reasons for discontinuing bolus were related to the complicated nature of regimen, including too complicated to calculate bolus doses (25.7%), too complicated to regulate food in relation to bolus (20.7%), and too complicated to keep track of taking two different insulins (18.6%). Respondents who stopped bolus reported more frequent HCP visits related to diabetes compared to the basal-bolus adherent and basal-bolus non-adherent groups.

Conclusion

Results suggest that the complicated nature of basal-bolus therapy contributes to the difficulties that T2D patients have with the regimen and to non-persistence. Physician and patient education may help patients address these treatment challenges to improve basal-bolus adherence and persistence, which could reduce healthcare resource use and costs. Less complex regimens may be appropriate for patients with persistent treatment difficulties.

Funding

Novo Nordisk A/S.
Literature
1.
go back to reference American Diabetes Association. Standards of medical care in diabetes–2015. Diabetes Care. 2015;38(Suppl 1):S1–93. American Diabetes Association. Standards of medical care in diabetes–2015. Diabetes Care. 2015;38(Suppl 1):S1–93.
2.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.CrossRefPubMed Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.CrossRefPubMed
3.
go back to reference Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications. 2015;29(2):295–301.CrossRefPubMed Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications. 2015;29(2):295–301.CrossRefPubMed
4.
go back to reference Blak BT, Smith HT, Hards M, Maguire A, Gimeno V. A retrospective database study of insulin initiation in patients with type 2 diabetes in UK primary care. Diabet Med. 2012;29(8):e191–8.CrossRefPubMed Blak BT, Smith HT, Hards M, Maguire A, Gimeno V. A retrospective database study of insulin initiation in patients with type 2 diabetes in UK primary care. Diabet Med. 2012;29(8):e191–8.CrossRefPubMed
5.
go back to reference Dale J, Martin S, Gadsby R. Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study. Prim Care Diabetes. 2010;4(2):85–9.CrossRefPubMed Dale J, Martin S, Gadsby R. Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study. Prim Care Diabetes. 2010;4(2):85–9.CrossRefPubMed
6.
go back to reference Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57(539):455–60.PubMedPubMedCentral Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57(539):455–60.PubMedPubMedCentral
7.
go back to reference Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med. 2007;22(4):453–8.CrossRefPubMedPubMedCentral Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med. 2007;22(4):453–8.CrossRefPubMedPubMedCentral
8.
go back to reference Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401–9.CrossRefPubMedPubMedCentral Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401–9.CrossRefPubMedPubMedCentral
9.
go back to reference Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–7.CrossRefPubMedPubMedCentral Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–7.CrossRefPubMedPubMedCentral
10.
go back to reference Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510–7.CrossRefPubMedPubMedCentral Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510–7.CrossRefPubMedPubMedCentral
11.
go back to reference Brod M, Kongso JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res. 2009;18(1):23–32.CrossRefPubMed Brod M, Kongso JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res. 2009;18(1):23–32.CrossRefPubMed
12.
go back to reference Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Factors associated with psychological insulin resistance in individuals with type 2 diabetes. Diabetes Care. 2010;33(8):1747–9.CrossRefPubMedPubMedCentral Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Factors associated with psychological insulin resistance in individuals with type 2 diabetes. Diabetes Care. 2010;33(8):1747–9.CrossRefPubMedPubMedCentral
13.
go back to reference Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.CrossRefPubMedPubMedCentral Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.CrossRefPubMedPubMedCentral
14.
go back to reference He X, Chen L, Wang K, Wu H, Wu J. Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis. Patient Prefer Adherence. 2017;11:237.CrossRefPubMedPubMedCentral He X, Chen L, Wang K, Wu H, Wu J. Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis. Patient Prefer Adherence. 2017;11:237.CrossRefPubMedPubMedCentral
15.
go back to reference Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.CrossRefPubMed Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.CrossRefPubMed
16.
go back to reference Donnelly LA, Morris AD, Evans JM, DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100(6):345–50.CrossRefPubMed Donnelly LA, Morris AD, Evans JM, DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100(6):345–50.CrossRefPubMed
17.
go back to reference Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS One. 2012;7(3):e32412.CrossRefPubMedPubMedCentral Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS One. 2012;7(3):e32412.CrossRefPubMedPubMedCentral
18.
go back to reference Banerji MA, Dunn JD. Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes. Am Health Drug Benefits. 2013;6(7):382–92.PubMedPubMedCentral Banerji MA, Dunn JD. Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes. Am Health Drug Benefits. 2013;6(7):382–92.PubMedPubMedCentral
19.
go back to reference Brod M, Nikolajsen A, Weatherall J, Pfeiffer KM. The economic burden of post-prandial hyperglycemia (PPH) among people with type 1 and type 2 diabetes in three countries. Diabetes Ther. 2016;7(1):75–90.CrossRefPubMedPubMedCentral Brod M, Nikolajsen A, Weatherall J, Pfeiffer KM. The economic burden of post-prandial hyperglycemia (PPH) among people with type 1 and type 2 diabetes in three countries. Diabetes Ther. 2016;7(1):75–90.CrossRefPubMedPubMedCentral
20.
go back to reference StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015.
21.
go back to reference Kumar M, Gupta S, Liu GG, Stankus AP. Demographics and health outcomes associated with adherence and non-adherence among type 2 diabetics in China. In: ISPOR 6th Asia Pacific conference; PDB31; Beijing, China, 2014. Kumar M, Gupta S, Liu GG, Stankus AP. Demographics and health outcomes associated with adherence and non-adherence among type 2 diabetics in China. In: ISPOR 6th Asia Pacific conference; PDB31; Beijing, China, 2014.
22.
go back to reference Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006;29(6):1249–55.CrossRefPubMed Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006;29(6):1249–55.CrossRefPubMed
23.
go back to reference Sayner R, Carpenter DM, Blalock SJ, et al. Accuracy of patient-reported adherence to glaucoma medications on a visual analog scale compared with electronic monitors. Clin Ther. 2015;37(9):1975–85.CrossRefPubMedPubMedCentral Sayner R, Carpenter DM, Blalock SJ, et al. Accuracy of patient-reported adherence to glaucoma medications on a visual analog scale compared with electronic monitors. Clin Ther. 2015;37(9):1975–85.CrossRefPubMedPubMedCentral
Metadata
Title
Diabetes Management and Healthcare Resource Use When Intensifying from Basal Insulin to Basal-Bolus: A Survey of Type 2 Diabetes Patients
Authors
Kathryn M. Pfeiffer
Amaury Basse
Xin Ying Lee
Laura Tesler Waldman
Publication date
01-10-2018
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 5/2018
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-018-0487-0

Other articles of this Issue 5/2018

Diabetes Therapy 5/2018 Go to the issue